Literature DB >> 2201791

Current status of tumor of the bowel following ureterosigmoidostomy: a review.

D A Husmann1, H M Spence.   

Abstract

In the final analysis the major question that arises is whether urinary diversion to the intact colon should be performed at all for benign conditions in which a relatively long life expectancy may be anticipated. In answer to this question we believe that if exstrophy is the problem early primary closure with the staged reconstruction should be attempted first. If such efforts are marred by persistent incontinence management with an artificial urinary sphincter should be considered. In individuals with multiple bladder dehiscences after attempts at primary bladder closure, or in an individual with persistent incontinence despite multiple procedures surgical alternates should include diversion by a bowel conduit, continent urinary diversion, a variant of the ureterosigmoidostomy or standard ureterosigmoidostomy. Indeed, despite the appropriate concern regarding the development of tumor in ureterosigmoidostomy, this diversion may still have a major role in the educational process of urology throughout the next decade. Specifically, we must apply the knowledge gained from our clinical and laboratory investigations of ureterosigmoid diversion to the current more popular means of diversion. Of particular concern are the clinical findings of adenocarcinoma in enteric augmentations. This discovery must serve as a warning for the possibility of urocolonic tumors developing within alternative continent urinary diversions within the next 20 to 30 years. Certainly, at least annual evaluations of any diversions are mandatory until we can define accurately the morbidity and mortality arising from our interventional management.

Entities:  

Mesh:

Year:  1990        PMID: 2201791     DOI: 10.1016/s0022-5347(17)39535-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  17 in total

1.  Invasive Squamous Carcinoma and Adenocarcinoma of an Unreconstructed Exstrophic Bladder with HPV Infection.

Authors:  Mesut Altan; Burak Çıtamak; Hakan Bahadır Haberal; Emrullah Söğütdelen; Ali Cansu Bozaci; Dilek Ertoy Baydar; Hasan Serkan Doğan; Serdar Tekgül
Journal:  Curr Urol       Date:  2016-05-20

Review 2.  Bladder augmentation: complications in the pediatric population.

Authors:  Peter D Metcalfe; Richard C Rink
Journal:  Curr Urol Rep       Date:  2007-03       Impact factor: 3.092

Review 3.  The role of imaging in pediatric bladder augmentation.

Authors:  Micheál Breen; Andrew Phelps; Carlos Estrada; Jeanne S Chow
Journal:  Pediatr Radiol       Date:  2015-04-24

4.  Urinary Diversions: Reviewing the most common types of diversion.

Authors:  I Davis
Journal:  Can Fam Physician       Date:  1991-06       Impact factor: 3.275

Review 5.  Carcinoma arising in enteric diversion or rectal neobladder for bladder exstrophy.

Authors:  R Ragu; G Meurette; M Kim; L Le Normand; P A Lehur
Journal:  Tech Coloproctol       Date:  2016-09-03       Impact factor: 3.781

6.  Application of the Mitrofanoff principle in children with severe impairment of bladder function.

Authors:  H A Heij; S Ekkelkamp; C G Moorman-Voestermans; A Vos
Journal:  Pediatr Surg Int       Date:  1997-04       Impact factor: 1.827

Review 7.  Tumour formation within intestinal segments transposed to the urinary tract.

Authors:  Robert Pickard
Journal:  World J Urol       Date:  2004-08-13       Impact factor: 4.226

8.  Ethical aspects of urinary diversion for women with irreparable obstetric fistulas in developing countries.

Authors:  L Lewis Wall; Steven D Arrowsmith; Brian D Hancock
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-01-24

9.  Pediatric enterocystoplasty: long-term complications and controversies.

Authors:  Eric A Kurzrock
Journal:  World J Urol       Date:  2008-10-10       Impact factor: 4.226

10.  Neuroendocrine cell hyperplasia in colonic tissue used for long term augmentation cystoplasty.

Authors:  K Oien; M Akyol; G Lindop
Journal:  J Clin Pathol       Date:  1998-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.